Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 Apr 14;288(6424):1105–1109. doi: 10.1136/bmj.288.6424.1105

Treatment of prolactinomas with megavoltage radiotherapy.

A Grossman, B L Cohen, M Charlesworth, P N Plowman, L H Rees, J A Wass, A E Jones, G M Besser
PMCID: PMC1441399  PMID: 6424752

Abstract

The outcome of treatment of 36 women with prolactinomas using megavoltage radiotherapy combined with interim dopamine agonists (bromocriptine, lysuride, pergolide) was reviewed; 16 of the women showed radiological evidence of a macroadenoma. The most common presenting symptom was secondary amenorrhoea; 26 of the patients had galactorrhoea. In 29 patients who wished to conceive the ovulation rate (as indicated by circulating progesterone concentrations) was 97% and the successful fertility rate 86%. No patient had enlargement of the tumour during pregnancy and there were no complications of radiotherapy. No further tumour enlargement was detected in serial skull radiographs, and an improvement in size of the fossa was noted in 45% of those assessed. When medical treatment was withdrawn a mean of 4.2 years (range 1-11) after radiotherapy in the 27 patients who had completed their families the serum prolactin concentration had fallen appreciably in 26 of them and later became normal in eight. The incidence of growth hormone deficiency rose from 24% of the whole group before radiotherapy to 79% afterwards. Only one patient required thyroxine, and one was receiving gonadotrophin. No patient became deficient in adrenocorticotrophic hormone. A regimen of megavoltage radiotherapy and interim bromocriptine allows women with prolactinomas safely to undergo pregnancy and results in the long term prospect of tumour shrinkage and control of hyperprolactinaemia.

Full text

PDF
1105

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergh T., Nillius S. J., Wide L. Menstrual function and serum prolactin levels after long-term bromocriptine treatment of hyperprolactinaemic amenorrhoea. Clin Endocrinol (Oxf) 1982 Jun;16(6):587–593. doi: 10.1111/j.1365-2265.1982.tb03175.x. [DOI] [PubMed] [Google Scholar]
  2. Gómez F., Reyes F. I., Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med. 1977 May;62(5):648–660. doi: 10.1016/0002-9343(77)90866-x. [DOI] [PubMed] [Google Scholar]
  3. Kleinberg D. L., Noel G. L., Frantz A. G. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977 Mar 17;296(11):589–600. doi: 10.1056/NEJM197703172961103. [DOI] [PubMed] [Google Scholar]
  4. Larkins R. G., Martin F. I. Hypopituitarism after extracranial irradiation: evidence for hypothalamic origin. Br Med J. 1973 Jan 20;1(5846):152–153. doi: 10.1136/bmj.1.5846.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Magyar D. M., Marshall J. R. Pituitary tumors and pregnancy. Am J Obstet Gynecol. 1978 Dec 1;132(7):739–751. doi: 10.1016/s0002-9378(78)80008-8. [DOI] [PubMed] [Google Scholar]
  6. Martin W. H., Cail W. S., Morris J. L., Constable W. C. Fibrosarcoma after high energy radiation therapy for pituitary adenoma. AJR Am J Roentgenol. 1980 Nov;135(5):1087–1090. doi: 10.2214/ajr.135.5.1087. [DOI] [PubMed] [Google Scholar]
  7. McGregor A. M., Scanlon M. F., Hall R., Hall K. Effects of bromocriptine on pituitary tumour size. Br Med J. 1979 Sep 22;2(6192):700–703. doi: 10.1136/bmj.2.6192.700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Modan B., Baidatz D., Mart H., Steinitz R., Levin S. G. Radiation-induced head and neck tumours. Lancet. 1974 Feb 23;1(7852):277–279. doi: 10.1016/s0140-6736(74)92592-6. [DOI] [PubMed] [Google Scholar]
  9. Nabarro J. D. Pituitary prolactinomas. Clin Endocrinol (Oxf) 1982 Aug;17(2):129–155. doi: 10.1111/j.1365-2265.1982.tb01573.x. [DOI] [PubMed] [Google Scholar]
  10. Pelkonen R., Grahne B., Hirvonen E., Karonen S. L., Salmi J., Tikkanen M., Valtonen S. Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy. Clin Endocrinol (Oxf) 1981 Apr;14(4):335–348. doi: 10.1111/j.1365-2265.1981.tb00618.x. [DOI] [PubMed] [Google Scholar]
  11. Randall R. V., Laws E. R., Jr, Abboud C. F., Ebersold M. J., Kao P. C., Scheithauer B. W. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc. 1983 Feb;58(2):108–121. [PubMed] [Google Scholar]
  12. Samaan N. A., Bakdash M. M., Caderao J. B., Cangir A., Jesse R. H., Jr, Ballantyne A. J. Hypopituitarism after external irradiation. Evidence for both hypothalamic and pituitary origin. Ann Intern Med. 1975 Dec;83(6):771–777. doi: 10.7326/0003-4819-83-6-771. [DOI] [PubMed] [Google Scholar]
  13. Samaan N. A., Leavens M. E., Jesse J. H., Jr Serum prolactin in patients with "functionless" chromophobe adenomas before and after therapy. Acta Endocrinol (Copenh) 1977 Mar;84(3):449–460. doi: 10.1530/acta.0.0840449. [DOI] [PubMed] [Google Scholar]
  14. Serri O., Rasio E., Beauregard H., Hardy J., Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983 Aug 4;309(5):280–283. doi: 10.1056/NEJM198308043090505. [DOI] [PubMed] [Google Scholar]
  15. Thorner M. O., Edwards C. R., Charlesworth M., Dacie J. E., Moult P. J., Rees L. H., Jones A. E., Besser G. M. Pregnancy in patients presenting with hyperprolactinaemia. Br Med J. 1979 Sep 29;2(6193):771–774. doi: 10.1136/bmj.2.6193.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wass J. A., Williams J., Charlesworth M., Kingsley D. P., Halliday A. M., Doniach I., Rees L. H., McDonald W. I., Besser G. M. Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed) 1982 Jun 26;284(6333):1908–1911. doi: 10.1136/bmj.284.6333.1908. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES